Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

101.65 +0.96 (+0.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 638,483
Open 100.51
Bid (Size) 98.00 (2)
Ask (Size) 109.30 (1)
Prev. Close 100.69
Today's Range 99.75 - 104.00
52wk Range 72.21 - 139.13
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)
From Axsome Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+16.4%
+16.4%
1 Month
-3.3%
-3.3%
3 Month
-21.3%
-21.3%
6 Month
+16.9%
+16.9%
1 Year
+29.5%
+29.5%

More News

Read More
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For May 5, 2025
Via Benzinga
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required
Via Benzinga
Exposures Product Safety
Demystifying Axsome Therapeutics: Insights From 11 Analyst Reviews
Via Benzinga
Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability
Via Stocktwits
Topics Stocks
Exposures Product Safety US Equities
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 Soaring Stocks Wth More Upside Potential
Via The Motley Fool
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Why Is Teva Stock Trading Higher On Tuesday?
Via Benzinga
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
Exposures Product Safety
Expert Outlook: Axsome Therapeutics Through The Eyes Of 16 Analysts
Via Benzinga
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis
Via The Motley Fool
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years
Via The Motley Fool
3 Monster Stocks in the Making
Via The Motley Fool
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
Via Benzinga
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)
Via Benzinga

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?
Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?
Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?
The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market
What is the current price of Axsome Therapeutics, Inc. - Common Stock?
The current price of Axsome Therapeutics, Inc. - Common Stock is 101.65
When was Axsome Therapeutics, Inc. - Common Stock last traded?
The last trade of Axsome Therapeutics, Inc. - Common Stock was at 06/23/25 04:00 PM ET
What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?
The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 4.80B
How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?
Axsome Therapeutics, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.